share_log

Silexion Reports New Preclinical Findings For SIL-204; Latest Preclinical Studies Reveal Significant Improvements In Stability, Efficacy, And KRAS Targeting Range For Next-generation SiRNA Candidate SIL-204

Benzinga ·  Oct 1 06:48

These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis of the human pancreatic cell line that bears the KRAS G12D mutation xenotransplanted into mice. Given that this mutation constitutes the largest segment of pancreatic cancer subtypes, it represents a significant in the development of SIL-204.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment